Pharmaceuticals
27 April 2021 - Posted by: Lukas Rengier
On 4 March 2021, the European Commission (Commission) opened a formal investigation into alleged anti-competitive conduct by the pharmaceutical company Teva. The Commission suspects Teva of having deployed a strategy with the intention of delaying the market entry of generic drugs that competed with Teva’s originator drug Copaxone. This may have amounted to an abuse › Read More
Patent settlements and competition law – guidance from Europe’s top court
15 April 2021 - Posted by: Lukas Rengier
On 25 March 2021, the European Court of Justice (ECJ) ruled for the second time on a “pay-for-delay” settlement. These are settlements of a patent dispute that involve payments or other value transfers from the originator manufacturer to the generic manufacturer in return for a delayed market entry. The ECJ dismissed appeals by the originator › Read More
Covid-19 – the UK’s vaccination programme so far
14 April 2021 - Posted by: Megan McMellon
As I said back in October, delivering a successful Covid-19 vaccine quickly was a huge challenge, but the diversity of the UK’s vaccine portfolio and the amendments made to the Human Medicines Regulations 2012 (HMRs) meant that the UK was in a strong position to carry out a successful mass vaccination programme as soon as › Read More
France – Mediator scandal: Servier laboratories convicted of aggravated deception and manslaughter
06 April 2021 - Posted by: Helene Laurent
On Monday 29 March, more than ten years after the opening of a criminal investigation and eighteen months after the start of an “out of the ordinary” trial, the Paris Criminal Court found Servier Laboratories guilty of “aggravated deception” and “manslaughter and involuntary injury” in the Mediator case. Servier laboratories marketed Mediator for years, an › Read More
23 March 2021 - Posted by: Thomas Masterman
Key points Working group’s goal is “concrete and actionable” updates to pharmaceutical merger analysis. Focus will include new theories of harm beyond the traditional approach of assessing overlaps in products and pipeline products. Stated intention is to take an “aggressive” approach to tackling anticompetitive pharmaceutical mergers. Overview On March 16, the U.S. Federal Trade Commission › Read More